COVID-19 survivors may be protected with just 1 vaccine dose, early studies suggest

As COVID-19 vaccine doses remain in short supply, new preliminary studies suggest only giving one dose to people who've recovered from the disease is enough to protect them from reinfection.
Past studies have shown COVID-19 survivors are left with antibodies that help protect them from reinfection for at least a few months, depending on how severe their infection was. Multiple not-yet-peer-reviewed studies still suggest they need another boost from a vaccine. But when they get the first dose of the two-dose regimens approved in the U.S., they see far higher levels of protection than people who get the first dose but weren't previously infected, suggesting that one shot is all they need for now.
"Everyone should get vaccinated. Not everybody needs two shots," Viviana Simon, a professor of microbiology at New York's Icahn School of Medicine at Mount Sinai and the author of one study, summed it up to The Wall Street Journal. "As long as we can't deliver as much vaccine to everybody who wants it, I think it's an important consideration." That first dose is especially important for COVID-19 survivors when it comes to fighting off the B.1.351 variant of the virus, as studies show COVID-19 survivors' natural immunity may not be as effective as a vaccine against the strain.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
These studies come after other research suggests the Pfizer/BioNTech vaccine is at least 85 percent effective after just one dose and Moderna is at least 92 percent, leading some scientists to recommend holding off on distributing second doses until more at-risk populations get the first.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kathryn is a graduate of Syracuse University, with degrees in magazine journalism and information technology, along with hours to earn another degree after working at SU's independent paper The Daily Orange. She's currently recovering from a horse addiction while living in New York City, and likes to share her extremely dry sense of humor on Twitter.
-
The Week contest: Hotel seal
Puzzles and Quizzes
By The Week US Published
-
New FBI Director Kash Patel could profit heavily from foreign interests
The Explainer Patel holds more than $1 million in Chinese fashion company Shein
By Justin Klawans, The Week US Published
-
Magazine solutions - February 28, 2025
Puzzles and Quizzes Issue - February 28, 2025
By The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published